Drug Shortage Report for TEVA-IRBESARTAN HCTZ
| Report ID | 100305 |
| Drug Identification Number | 02330520 |
| Brand name | TEVA-IRBESARTAN HCTZ |
| Common or Proper name | TEVA-IRBESARTAN/HCTZ 300/12.5MG |
| Company Name | TEVA CANADA LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | HYDROCHLOROTHIAZIDE IRBESARTAN |
| Strength(s) | 12.5MG 300MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL |
|
Packaging sizes (GTIN)
Click here to see a list of all reports for this drug. |
(See additional packaging sizes) |
| Additional packaging sizes | 100 |
| ATC code | C09DA |
| ATC description | ANGIOTENSIN II ANTAGONISTS, COMBINATIONS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2019-12-05 |
| Estimated end date | 2021-09-30 |
| Actual end date | 2021-09-09 |
| Shortage status | Resolved |
| Updated date | 2021-09-10 |
| Company comments | Allocating to 100% of our market. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.